Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide

Abstract

Using the commercially available antidiabetic drug exenatide (exendin-4) as a model peptide, we designed a novel exenatide derivative, termed LEX-1, comprising a 12-mer albumin-binding peptide, a protease-sensitive linker and a native exenatide.